<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201008234618N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2010-09-09</date_registration>
      <primary_sponsor>Sediqeh Khalili (personal)</primary_sponsor>
      <public_title>Clinical Trial "Assessment of the effect of Diclofenac gel and EMLA" ointment"</public_title>
      <acronym></acronym>
      <scientific_title>Clinical Trial "Assessment of the effect of Diclofenac gel and EMLA ointment  on vein puncture pain severity with vein catheter in patient undergoing cesarean section"</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2010-04-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/4955</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Diclofenac gel on vein puncture pain severity with vein catheter. Condition 2: EMLA ointment  on vein puncture pain severity with vein catheter.</hc_freetext>
      <i_freetext>Intervention 1: Researcher put the size of 2 g of EMLA ointment (EMLA ointment 5% mixture of lidocaine 2.5% and 2.5% prilocaine Manufactured by Tehran Chemie Pharmaceutical Co. Tehran - Iran, that containing 30 - gram tubes with confirmation Ministry of Health) in the level of the 2.5 × 4 cm EMLA group ointment on the behind at the left hand, before an hour catheter insertion and covered the area with transparent dressing. Intervention 2: Researcher put the size of 100 mg of diclofenac gel (diclofenac gel 1% Each 100 grams contains: diclofenac Diethyl ammonium equivalent to diclofenac sodium 1 g, Manufactured by Behvzan Co. Rasht - Iran that containing 60 grams tubes with confirmation Ministry of Health) in the level of the 1.9 × 3.8 cm diclofenac group gel on the behind at the left hand, before an hour catheter insertion and covered the area with transparent dressing. Intervention 3: Researcher put the size of 100 mg of Vaseline ointment (Vaseline ointment compounds that liquid paraffin and glycerin, Lanolin and Fragrance free, Manufactured by Pars Hayan Co. Iran that containing 45 grams tubes with confirmation Ministry of Health) in the level of the 1.9 × 3.8 cm placed group on the behind at the left hand, before an hour catheter insertion and covered the area with transparent dressing.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sediqeh Khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Joybar Three-way, Imam Square</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815733971</zip>
        <telephone>+98 15 1214 4000</telephone>
        <email>khalili@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sediqeh Khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati, Zargndeh</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19168</zip>
        <telephone>+98 21220066607</telephone>
        <email>shomia@ymail.com</email>
        <affiliation>Islamic Azad University, Tehran Medical</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Study Entry Requirements: aged 18 to 40 years; don’t have any defect in terms of mental and visual and verbal ability; Patients who doesn’t have any sensitivity to local anaesthetics or allergy to NSAIDs; haven’t used analgesics during the previous 24 hours; don’t have Favism, methemoglobin, liver and kidney disease, asthma, skin allergies, skin dermatitis, wound in the area assigned for intervention, active gastrointestinal bleeding, allergies to topical anaesthetics and non steroidal anti-inflammatory drugs included in this study. Study Exclusion: if the insertion vein catheter be unsuccessful in the first attempt or the caesarean section become an emergency operation.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y45.3</hc_code>
      <hc_code>Y48.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other nonsteroidal anti-inflammatory drugs</hc_keyword>
      <hc_keyword>Local anaesthetics</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Researcher put the size of 2 g of EMLA ointment (EMLA ointment 5% mixture of lidocaine 2.5% and 2.5% prilocaine Manufactured by Tehran Chemie Pharmaceutical Co. Tehran - Iran, that containing 30 - gram tubes with confirmation Ministry of Health) in the level of the 2.5 × 4 cm EMLA group ointment on the behind at the left hand, before an hour catheter insertion and covered the area with transparent dressing.</i_keyword>
      <i_keyword>Researcher put the size of 100 mg of diclofenac gel (diclofenac gel 1% Each 100 grams contains: diclofenac Diethyl ammonium equivalent to diclofenac sodium 1 g, Manufactured by Behvzan Co. Rasht - Iran that containing 60 grams tubes with confirmation Ministry of Health) in the level of the 1.9 × 3.8 cm diclofenac group gel on the behind at the left hand, before an hour catheter insertion and covered the area with transparent dressing.</i_keyword>
      <i_keyword>Researcher put the size of 100 mg of Vaseline ointment (Vaseline ointment compounds that liquid paraffin and glycerin, Lanolin and Fragrance free, Manufactured by Pars Hayan Co. Iran that containing 45 grams tubes with confirmation Ministry of Health) in the level of the 1.9 × 3.8 cm placed group on the behind at the left hand, before an hour catheter insertion and covered the area with transparent dressing.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Vein puncture pain severity with vein catheter. Timepoint: 3-5 minutes after vein catheter installation. Method of measurement: Visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Short-term effects of topical drugs diclofenac gel, anesthetic cream EMLA  and vaseline cream. Timepoint: application local medications later One hour. Method of measurement: Checklist of short-term effects of topical drugs.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sediqeh Khalili (personal)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-04-29</approval_date>
        <contact_name>Islamic Azad University, Medical Sciences Tehran</contact_name>
        <contact_address>Shariaty, Zargande Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
